Plain English Summary
Background and study aims
We are carrying out a study on patients undergoing negative pressure wound therapy dressing changes. Common analgesics (painkillers) such as local anesthesia with lidocaine alone are often not effective for this procedure. Opioids are the most effective analgesics but their use is limited by numerous side effects, such as nausea, vomiting, constipation, urinary retention, dysphoria (an emotional state characterized by anxiety, depression or unease), euphoria (a feeling or state of intense excitement and happiness), altered cognitive (mental) function and hypoventilation (slow breathing). Other sedatives used for procedural sedation such as propofol or benzodiazepines offer no analgesia (pain relief) and may cause hypoventilation, alterations in hemodynamics and drowsiness. Ketamine is an old anaesthetic agent that also has analgesic properties. Ketamine also reduces the need for opioids and thus helps to reduce side effects caused by opioid medication.
Who can participate?
Adult patients aged over 18 undergoing elective wound dressing changes in the plastic surgery unit. 23 patients will be enrolled in the study.
What does the study involve?
The wound dressing changes will take place every 3-4 days for each patient. Each patient will be randomly allocated to receive either S-ketamine or saline on their first procedure and then on the second procedure the patient will be given the remaining medicine. Each patient will be given midazolam as a premedication before the procedure and a solution containing lidocaine with saline. If the pain is too great during the procedure, the patient will be given fentanyl as a rescue medication.
What are the possible benefits and risks of participating?
The possible benefits of participating in the study are improved analgesia during the procedure, reduced need for rescue medication (fentanyl) and fewer side effects caused by opioid medication. Possible risks are the side effects caused by ketamine. The most common side effect of ketamine is altered mental state. However, that can be prevented by giving midazolam as a premedication.
Where is the study run from?
The study is run from the Helsinki University Central Hospital Töölö Hospital, Finland.
When is the study starting and how long is it expected to run for?
It is anticipated that recruitment for the study will start in April 2014. Participants will be enrolled on the study for a period of one year, recruiting the last patient on April 2015. However, the recruitment period will be extended if necessary until 23 patients are enrolled.
Who is funding the study?
Helsinki University Central Hospital, Finland.
Who is the main contact?
Dr Vesa Kontinen
Dr Elina Brinck
Trial website
Additional identifiers
EudraCT number
2013-005114-35
ClinicalTrials.gov number
Protocol/serial number
N/A
Study information
Scientific title
S-ketamine to reduce negative pressure wound therapy dressing change associated pain: a prospective, randomized, blinded cross-over study
Acronym
KETAPLAST
Study hypothesis
S-ketamine effectively alleviates procedural pain and reduces the need for rescue medication (fentanyl) during negative pressure wound therapy dressing change compared to local anaesthesia.
Ethics approval
Operative ethics committee of the Helsinki University Central Hospital, 12t/02/2014, ref: 38/13/03/02/2014
Study design
Prospective randomized blinded cross-over study
Primary study design
Interventional
Secondary study design
Randomised cross over trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
See additional files
Condition
Procedural pain related to negative pressure wound therapy dressing changes
Intervention
1. Intervention group: S-ketamine dose 0.25 mg/kg will be administered during negative pressure wound therapy dressing change in addition to local anaesthesia
2. Control group: placebo (saline)
The wound dressing changes will take place every 3-4 days for each patient. Each patient will be randomized to receive either S-ketamine or saline on their first procedure and then on the second procedure, she or he will be given the remaining medicine. Each patient will be given midazolam as a premedication before the procedure and a solution containing Lidocaine 1% with saline will be absorbed into the tissue treated. If the pain score (NRS scale) exceeds 5 during the procedure, she or he will be given fentanyl 0.5-1 ug/kg as a rescue medication.
Intervention type
Drug
Phase
Not Applicable
Drug names
S-ketamine
Primary outcome measures
1. Pain measured using the NRS scale during the procedure, at the end of the procedure, and at three months after the procedure
2. Possible need for rescue medicine (fentanyl) during the procedure and, if needed, how much
Secondary outcome measures
To evaluate and compare the possible side effects such as altered mental state, desaturation, changes in blood pressure and heart rate associated with the treatment of S-ketamine or rescue medication (fentanyl):
1. Confusion measured with Richmond Agitation Sedation Scale (RASS) at 30 minutes and 60 minutes after the drug investigated (S-ketamine or placebo) has been given
2. Saturation with pulse oximetry (SpO2 %) at 15 minutes, 30 minutes and 60 minutes after the drug investigated (S-ketamine or placebo) has been given
3. Hemodynamic parameters (blood pressure mmHg and pulse beats/minute) at 15 minutes, 30 minutes and 60 minutes after the drug investigated (S-ketamine or placebo) has been given
Overall trial start date
01/04/2014
Overall trial end date
31/12/2018
Reason abandoned
Eligibility
Participant inclusion criteria
Adult patients over 18 years undergoing elective negative pressure wound therapy wound dressing changes in the plastic surgery unit
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
23
Participant exclusion criteria
1. Body mass index over 35
2. Unstable ischaemic cardiac disease
3. Increased intracranial pressure
4. Increased intraocular pressure
5. Gravidity
6. Lactation
7. Hypersensitivity or allergy to ketamine, fentanyl or midazolam
8. Severe psychiatric disease
9. Inability to use the Numerical Rating Scale (NRS) pain scale
Recruitment start date
01/04/2014
Recruitment end date
31/12/2017
Locations
Countries of recruitment
Finland
Trial participating centre
Helsinki University Central Hospital
Helsinki
00029
Finland
Sponsor information
Organisation
Helsinki University Central Hospital (Finland)
Sponsor details
c/o Vesa Kontinen
Jorvi Hospital
Turuntie 150
PB 800
Helsinki
00029
Finland
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Hospital/treatment centre
Funder name
Helsinki University Central Hospital (Finland)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
This clinical trial will be a part of a doctoral thesis (In Finland, 3-5 trials are required for PhD in Medicine). Plans to publish the results of in a high-impact peer reviewed journal during 2018-2019.
IPD Sharing plan:
The datasets generated during and/or analysed during the current study are/will be available upon request from elina.brinck@hus.fi
Intention to publish date
31/12/2019
Participant level data
Available on request
Results - basic reporting
Publication summary
Publication citations
Additional files
- ISRCTN90985804_PIS_19Jan16_Finnish.doc Uploaded 19/01/2017